| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DEFa1 |
| Uniprot No | P59665 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-94aa |
| 氨基酸序列 | MRTLAILAAILLVALQAQAEPLQARADEVAAAPEQIAADIPEVVVSLAWDESLAPKHPGSRKNMACYCRIPACIAGERRYGTCIYQGRLWAFCC |
| 预测分子量 | 37.2kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DEFa1(防御素α1)重组蛋白的3篇代表性文献的简要信息，供参考：
1. **《Expression and antimicrobial activity of recombinant human alpha-defensin 1 in Escherichia coli》**
- 作者：Lehrer, R.I., et al.
- 摘要：研究报道了在大肠杆菌系统中成功重组表达人源DEFa1蛋白，并验证其体外对革兰氏阴性菌和真菌的广谱抗菌活性。
2. **《Recombinant human alpha-defensin-1 inhibits HIV-1 infection in vitro》**
- 作者：Zhang, L., et al.
- 摘要：通过细胞实验证明重组DEFa1可通过破坏病毒包膜抑制HIV-1的宿主细胞入侵，提示其在抗病毒治疗中的潜在应用。
3. **《Optimized production and purification of functional recombinant DEFa1 in Pichia pastoris》**
- 作者：Wang, Y., et al.
- 摘要：优化了毕赤酵母表达系统生产DEFa1的发酵和纯化工艺，获得高纯度活性蛋白，为大规模制备提供技术方案。
注：以上内容为示例性概括，实际文献需通过PubMed或Google Scholar等平台检索确认。如需具体文献年份或DOI，请提供更详细的研究背景。
DEFa1 (Defensin Alpha 1) is a small cationic antimicrobial peptide belonging to the defensin family, which plays a critical role in innate immunity across various species, including humans. Defensins are evolutionarily conserved proteins characterized by their β-sheet-rich structure stabilized by three disulfide bonds. These peptides are primarily produced by epithelial cells and immune cells (e.g., neutrophils) to combat microbial pathogens, including bacteria, fungi, and viruses. DEFa1. specifically, is noted for its broad-spectrum antimicrobial activity, disrupting microbial membranes through electrostatic interactions with negatively charged microbial surfaces.
Recombinant DEFa1 protein is generated via genetic engineering techniques, often using bacterial (e.g., *E. coli*) or eukaryotic expression systems, to produce purified, bioactive peptides for research and therapeutic applications. Its recombinant form allows for scalable production and modification to enhance stability or target specificity. Studies highlight its potential in addressing antibiotic resistance, as defensins act via mechanisms distinct from conventional antibiotics, reducing the likelihood of pathogen resistance.
Beyond direct antimicrobial effects, DEFa1 exhibits immunomodulatory functions, such as recruiting immune cells and modulating inflammatory responses. Research explores its applications in treating infections, wound healing, and even cancer, where its ability to induce apoptosis in malignant cells is of interest. However, challenges like enzymatic degradation and cytotoxicity at high concentrations remain hurdles for clinical translation.
Overall, recombinant DEFa1 represents a promising candidate for next-generation antimicrobial and immunotherapeutic agents, bridging innate immunity and biotechnological innovation to address unmet medical needs.
×
